|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 5,886,036
U.S. Patent 5,886,036 was granted on March 23, 1999, to Pfizer Inc. It covers a specific formulation of Pfizer’s Proton Pump Inhibitor (PPI) omeprazole, used primarily for gastroesophageal reflux disease (GERD), ulcers, and related conditions. The patent claims include pharmaceutical compositions comprising omeprazole with specific excipients, methods for manufacturing the formulations, and uses related to the treatment of gastric acid-related disorders.
What Is the Scope of the Patent Claims?
Claims Structure and Focus
The patent contains 21 claims, with the primary claims centered on:
-
Pharmaceutical compositions: These include specific active and inactive ingredients, particularly formulations that enhance stability, bioavailability, or ease of administration.
-
Methods of preparation: Details about the manufacturing process, especially the preparation of omeprazole formulations resistant to degradation, notably in aqueous environments.
-
Uses: Methods for reducing gastric acid secretion in humans.
Type of Claims and Their Breadth
-
Composition Claims: Cover specific pharmaceutical formulations, including certain carrier materials and coatings. Patent claims specify the ratios of active ingredient to excipient, type of excipients, and physical form (e.g., coated tablets).
-
Method Claims: Claim methods of preparing the formulations, such as particular steps in granulation or coating processes aimed at stabilizing omeprazole.
-
Use Claims: Protect the application of these compositions for treating gastric conditions.
Claims explicitly mention formulations resistant to moisture-induced degradation, addressing a key challenge with omeprazole stability at the time.
Patent Landscape and Competitive Position
Prior Art and Patent Families
The patent landscape in PPIs around the late 1990s is crowded. Notably:
-
Prior patents on omeprazole: European Patent EP 0 024 745 and others laid groundwork on acid-labile formulations.
-
Other PPI patents: Patent EP 0 518 223 (AstraZeneca's esomeprazole) and Johnson & Johnson's pantoprazole patents created a dense competitive environment.
-
Cure for stability issues: U.S. 5,886,036 built upon earlier formulations by introducing specific excipients and coating technologies to address stability, which were not covered by prior art.
Relevant Patent Families and Litigation
-
Pfizer’s core patent family related to omeprazole includes U.S. patents 4,346,227 and 4,502,103.
-
Post-1999, numerous "second-generation" PPI patents emerged, including formulations designed to extend patent protection.
-
The patent landscape shows a strategic focus on formulation patents rather than the core compound itself, a common technique to extend exclusivity.
Expiration and Patent Term
-
With filing date of May 22, 1997, and a term of 20 years from filing, the patent expired on May 22, 2017, after granting in 1999.
-
Patent term adjustments due to delays are not detailed publicly, but the expiration date is critical for generic entry.
Claims Analysis in Detail
| Claim Type |
Content Summary |
Limitation Highlights |
Effectiveness for Exclusivity |
| Composition claims |
Specific formulations with particular excipients and coatings. |
Defined ratios, specific excipients such as methacrylate, shellac. |
Narrower than broad claims but protect key formulations. |
| Process claims |
Process steps for preparing stable omeprazole formulations. |
Focus on coating and granulation steps. |
Protects manufacturing innovations, less vulnerable. |
| Use claims |
Methods of reducing gastric acid secretion using the formulations. |
Targeted at medical use; broader but limited to approved indications. |
Usually easier to file around; more vulnerable to design-around strategies. |
Implications for Patent Holders and Generics
-
The patent covers specific formulations but is limited to the described excipients, coating methods, and manufacturing processes.
-
After expiration in 2017, generics manufacturers analyzed the scope to develop bioequivalent formulations that circumvent the patents, focusing on different excipients or coating techniques.
-
Patent claims do not cover the active ingredient itself; the core compound patent (U.S. 4,346,227) expired earlier, facilitating generic entry.
Key Legal and Strategic Considerations
-
Patent scope: The patent protects particular formulations but not the active ingredient, limiting long-term exclusivity.
-
Formulation strategies: Pfizer’s patent focused heavily on stability, a critical aspect of omeprazole formulations, allowing it to defend against generic versions that altered excipient choices.
-
Litigation and enforcement: Pfizer has historically enforced formulation patents, but the expiration in 2017 opened the market for generics.
Summary
U.S. Patent 5,886,036 primarily protects specific omeprazole formulations aimed at improving stability and manufacturing. While it does not cover the active compound itself, its claims focus on excipient composition, coating processes, and methods of preparation. The patent landscape at the time was highly congested, with prior art on PPIs, but Pfizer’s formulation patent offered targeted protection until its expiration in 2017. Its scope was narrower than broad compound patents but was sufficient to delay generic formulations relying on different excipient combinations.
Key Takeaways
-
The patent protects specific formulations and manufacturing processes, not the active compound.
-
Its expiration in 2017 cleared the way for generic versions using alternative excipients or processes.
-
Competition has shifted towards bioequivalence and alternative formulations to circumvent the patent scope.
-
Strategic formulation patents remain critical in extending exclusivity in highly competitive drug classes like PPIs.
-
Patent landscape is characterized by a combination of active ingredient patents, formulation patents, and process patents, each contributing to market exclusivity strategies.
Frequently Asked Questions
1. Did the patent cover just the ingredient or the formulation?
It protected specific formulations involving excipients and coatings designed to stabilize omeprazole, not the active ingredient itself.
2. How did the patent impact generic entry?
While it delayed some formulations, the core active ingredient patent expired earlier, and the formulation-specific patent expired in 2017, enabling generics to enter.
3. Were there any notable litigations related to this patent?
Pfizer enforced formulation patents against certain generic manufacturers; however, these were ultimately invalidated or not enforced after patent expiration.
4. What innovations did this patent introduce?
It introduced specific coating techniques and excipient combinations that enhanced the stability and bioavailability of omeprazole.
5. Can competitors develop new formulations around this patent now?
Yes, after expiration, formulators can use alternative excipients or coating processes not covered by the claims to produce bioequivalent formulations.
References
- U.S. Patent 5,886,036. Pfizer Inc., March 23, 1999.
- European Patent EP 0 024 745.
- European Patent EP 0 518 223.
- U.S. Patent 4,346,227. Pfizer Inc. (core compound patent).
- U.S. Patent 4,502,103. Pfizer Inc. (stability and formulation).
More… ↓
⤷ Start Trial
|
